Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Rhabdomyosarcoma 8Wilms Tumor 6Sarcoma 6Malignant mesenchymal tumor 4Rhabdomyosarcoma, Embryonal 2Kidney Neoplasms 2Hydatidiform Mole 2Stage I Mixed Cell Type Kidney Wilms Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma, Alveolar 1Pleuropulmonary blastoma 1Gestational Trophoblastic Disease 1Fibrosarcoma 1Choriocarcinoma 1Carcinoma, Renal Cell 1Beckwith-Wiedemann Syndrome 1

Interventions

pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1merphos 1Thiotepa 1Specimen Handling 1Second-Look Surgery 1Reoperation 1Radiotherapy 1Radiation 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1Mesna 1Magnetic Resonance Spectroscopy 1Leucovorin 1Ifosfamide 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Dactinomycin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Choriocarcinoma × Dactinomycin × Clear all
NCT01535053 2022-08-12

Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia

GOG Foundation

Phase 3 Completed
57 enrolled 12 charts

Choriocarcinoma, Hydatidiform Mole

Data powered by HemOnc (CC BY 4.0) Colophon âš¡